Systematic shifts in cystatin C between 2006 and 2010

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 8, 2011, Pages 1952-1955

  Maahs, David M ^a,b   Jalal, Diana ^b   McFann, Kim ^a   Rewers, Marian ^a,c   Snell Bergeon, Janet K ^a,c  

^a UNIVERSITY OF COLORADO DENVER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c Department of Civil and Environmental Engineering at Colorado State University and the Department of Environmental and Occupational Health at the Colorado School of Public Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTATIN C;

ARTICLE; BLOOD SAMPLING; CLINICAL LABORATORY; CORONARY ARTERY CALCIFICATION; FOLLOW UP; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS;

ADULT; BIOLOGICAL MARKERS; COLORADO; CYSTATIN C; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HUMANS; KIDNEY FUNCTION TESTS; MIDDLE AGED; OBSERVER VARIATION; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 80051556386     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.11271210     Document Type: Article

References (21)

1. Laterza OF, Price CP, Scott MG: Cystatin C: An improved estimator of glomerular filtration rate? Clin Chem 48: 699-707, 2002
2. Dharnidharka VR, Kwon C, Stevens G: Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis. Am J Kidney Dis 40: 221-226, 2002
3. Buysschaert M, Joudi I, Wallemacq P, Hermans MP. Performance of serum cystatin-C versus serum creatinine in subjects with type 1 diabetes. Diab Care 26:1320, 2003
4. Filler G, Bokenkamp A, Hofmann W, Le BT, Martinez-Bru C, Grubb A: Cystatin C as a marker of GFR-History, indications, and future research. Clin Biochem 38: 1-8, 2005
5. Tan GD, Lewis AV, James TJ, Altmann P, Taylor RP, Levy JC: Clinical usefulness of cystatin C for the estimation of glomerular filtration rate in type 1 diabetes: Reproducibility and accuracy compared with standard measures and iohexol clearance. Diab Care 25: 2004-2009, 2002
6. Maahs DM, Ogden LG, Kretowski A, Snell-Bergeon JK, Kinney GL, Berl T, Rewers M: Serum cystatin C predicts progression of subclinical coronary atherosclerosis in persons with type 1 diabetes mellitus. Diabetes 56: 2774-2779, 2007
7. Koenig W, Twardella D, Brenner H, Rothenbacher D: Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: More than simply a marker of glomerular filtration rate. Clin Chem 51: 321-327, 2005
8. Luc G, Bard JM, Lesueur C, Arveiler D, Evans A, Amouyel P, Ferrieres J, Juhan-Vague I, Fruchart JC, Ducimetiere P: Plasma cystatin-C and development of coronary heart disease: The PRIME study. Atherosclerosis 185: 375-380, 2006
9. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C: Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 352: 2049-2060, 2005
10. Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, Seliger SL, Kestenbaum B, Psaty B, Tracy RP, Siscovick DS: Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 145: 237-246, 2006
11. Shlipak MG, Wassel Fyr CL, Chertow GM, Harris TB, Kritchevsky SB, Tylavsky FA, Satterfield S, Cummings SR, Newman AB, Fried LF: Cystatin C and mortality risk in the elderly: The Health, Aging, and Body Composition study. J Am Soc Nephrol 17: 254-261, 2006
12. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) National Kidney Disease Education Program (NKDEP) Laboratory Working Group Meeting. American Association of Clinical Chemistry Annual Meeting, Chicago, IL, July 22, 2009
13. Maahs DM, Kinney GL, Wadwa P, Snell-Bergeon JK, Dabelea D, Hokanson J, Ehrlich J, Garg S, Eckel RH, Rewers MJ: Hypertension prevalence, awareness, treatment, and control in an adult type 1 diabetes population and a comparable general population. Diab Care 28: 301-306, 2005
14. Dabelea D, Kinney G, Snell-Bergeon JK, Hokanson JE, Eckel RH, Ehrlich J, Garg S, Hamman RF, Rewers M: Effect of type 1 diabetes on the gender difference in coronary artery calcification: A role for insulin resistance?: The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study. Diabetes 52: 2833-2839, 2003
15. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van LF, Greene T, Coresh J: A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612, 2009
16. Finney H, Newman DJ, Gruber W, Merle P, Price CP. Initial evaluation of cystatin C measurement by particle-enhanced immunonephelometry on the Behring nephelometer systems (BNA, BN II). Clin Chem 43: 1016-1022, 1997
17. Erlandsen EJ, Randers E, Kristensen JH: Evaluation of the Dade-Behring N latex cystatin C assay on the Dade-Behring nephelometer II system. Scand J Clin Lab Invest 59: 1-8, 1999
18. Shlipak MG: Cystatin C: Research priorities targeted to clinical decision making. Am J Kidney Dis 51: 358-361, 2008
19. Murthy K, Stevens LA, Stark PC, Levey AS: Variation in the serum creatinine assay calibration: A practical application to glomerular filtration rate estimation. Kidney Int 68: 1884-1887, 2005
20. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van LF: Expressing the Modification of Diet in Renal Disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 53: 766-772, 2007
21. Geistanger A, Arends S, Berding C, Hoshino T, Jeppsson JO, Little R, Siebelder C, Weykamp C: Statistical methods for monitoring the relationship between the IFCC reference measurement procedure for hemoglobin A1c and the designated comparison methods in the United States, Japan, and Sweden. Clin Chem 54: 1379-1385, 2008